Last reviewed · How we verify

Quetiapine Fumarate Sustained Release

AstraZeneca · FDA-approved active Small molecule

Quetiapine Fumarate Sustained Release is a Atypical antipsychotic Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive therapy). Also known as: Seroquel XR.

Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain.

Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive therapy).

At a glance

Generic nameQuetiapine Fumarate Sustained Release
Also known asSeroquel XR
SponsorAstraZeneca
Drug classAtypical antipsychotic
TargetDopamine D2 receptor, Serotonin 5-HT2A receptor
ModalitySmall molecule
Therapeutic areaPsychiatry
PhaseFDA-approved

Mechanism of action

Quetiapine blocks dopamine and serotonin receptors, which reduces psychotic symptoms and stabilizes mood. The sustained-release formulation provides extended drug delivery over 24 hours, allowing once-daily dosing while maintaining therapeutic levels. This mechanism is thought to normalize neurotransmitter activity in brain regions associated with psychosis, mania, and depression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Quetiapine Fumarate Sustained Release

What is Quetiapine Fumarate Sustained Release?

Quetiapine Fumarate Sustained Release is a Atypical antipsychotic drug developed by AstraZeneca, indicated for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive therapy).

How does Quetiapine Fumarate Sustained Release work?

Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain.

What is Quetiapine Fumarate Sustained Release used for?

Quetiapine Fumarate Sustained Release is indicated for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive therapy).

Who makes Quetiapine Fumarate Sustained Release?

Quetiapine Fumarate Sustained Release is developed and marketed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Quetiapine Fumarate Sustained Release also known as anything else?

Quetiapine Fumarate Sustained Release is also known as Seroquel XR.

What drug class is Quetiapine Fumarate Sustained Release in?

Quetiapine Fumarate Sustained Release belongs to the Atypical antipsychotic class. See all Atypical antipsychotic drugs at /class/atypical-antipsychotic.

What development phase is Quetiapine Fumarate Sustained Release in?

Quetiapine Fumarate Sustained Release is FDA-approved (marketed).

What are the side effects of Quetiapine Fumarate Sustained Release?

Common side effects of Quetiapine Fumarate Sustained Release include Somnolence/sedation, Dry mouth, Dizziness, Weight gain, Headache, Constipation.

What does Quetiapine Fumarate Sustained Release target?

Quetiapine Fumarate Sustained Release targets Dopamine D2 receptor, Serotonin 5-HT2A receptor and is a Atypical antipsychotic.

Related